Paul August, PhD, is a distinguished neuroscientist and biotech executive with over 25 years of experience advancing drug discovery programs for neurodegenerative and genetically-driven diseases. He currently serves as the Chief Scientific Officer (CSO) at ReviR Therapeutics, where he leads the development of innovative RNA-targeted therapies for neurological disorders such as Huntington’s disease and ALS. His work at ReviR has been pivotal in advancing two development candidates toward clinical trials, driving the company’s strategic vision, and expanding its global drug discovery platforms. Paul is also the Co-Founder of AcuraStem, a biotechnology company dedicated to developing breakthrough treatments for ALS and other neurodegenerative conditions. In part due to his leadership, AcuraStem progressed its ALS drug candidate to clinical development and secured significant research funding, including the award of multiple Small Business Innovation Research (SBIR) grants. Paul previously served as Vice President of the Genetically Defined Disease preclinical research at Agios Pharmaceuticals, where he was instrumental in driving preclinical drug discovery strategies for rare genetic diseases. His extensive experience in translational medicine and cross-functional leadership has positioned him as a key figure in the biotech industry, with a proven track record of advancing therapies for serious, unmet medical needs. Before his current roles, Paul spent over two decades at Sanofi, where he held senior leadership positions and played a key role in the company’s global drug discovery efforts. As Senior Director, he led multiple research areas and fostered partnerships with leading academic institutions and patient advocacy foundations. Throughout his career, Paul has demonstrated a passion for developing transformative therapies, with a deep focus on rare neurodegenerative diseases. He holds a Ph.D. from the University of Minnesota and has authored over 30 scientific publications, co-invented eight patents, and secured multiple research grants, reflecting his commitment to scientific innovation and therapeutic advancement.